An Unexpected Turn in Texas Court
In a dramatic turn of events, an $86 million lawsuit involving medical giant Medtronic over their stent sales has been declared a mistrial. The decision came after a standstill among jurors was reported to U.S. District Judge Alan Albright in Waco, Texas. One juror’s steadfast refusal to alter their stance created an impasse that four-and-a-half hours of deliberations could not resolve.
Mistrial Called In $86M Stent Patent Case Against Medtronic: Persistent Legal Battle Over Stent Patent
For nearly four years, the legal team of Timur Sarac, a prominent former surgeon from the Cleveland Clinic, has pursued claims against Medtronic. Sarac alleges that Medtronic’s Endurant stents, introduced in 2010, infringe on his 2006 patent. This patent outlines a unique stent graft design featuring telescoping arms shaped like an “M”. During the closing arguments, Christopher Gaspar of Milbank LLP emphasized to the jury that the evidence justified the $86 million claim.
Mistrial Called In $86M Stent Patent Case Against Medtronic: Medtronic’s Knowledge and Alleged Evasion
Christopher Gaspar highlighted a cryptic email from a Medtronic executive which suggested foreknowledge of the impending lawsuit, bolstering Sarac’s case. The phrase “Let’s discuss live,” as used in the email, was portrayed as an attempt to avoid leaving a written record. This, Gaspar argued, was tantamount to a “smoking gun” in the civil litigation context.
Mistrial Called In $86M Stent Patent Case Against Medtronic: Key Testimonies and Absences
The trial also shed light on a 2006 meeting between Sarac and Trevor Greenan, a key figure in developing Medtronic’s contested stent. Despite Greenan’s rapid dismissal of any influence from Sarac during a deposition, his absence at the trial was conspicuous. Gaspar rhetorically noted that if he were innocent of the accusations, he would have appeared to testify, regardless of personal commitments.
Jury Division Leads to Mistrial
The jury was visibly divided shortly after deliberations began, culminating in a note from a juror to Judge Albright expressing their unyielding position. This note hinted at deep-seated convictions among the jurors that would not be swayed by extended deliberation.
Reaction from Medtronic’s Legal Team
In response to the mistrial, Medtronic’s attorney Thomas Melsheimer described the outcome as relatively favorable, given that the trial concluded without a financial award against them. He highlighted the complexities of defending such a high-stakes lawsuit.
Ongoing Implications and Future Steps
While the mistrial represents a temporary setback, the continuation of this legal saga is anticipated as both parties reassess their strategies. Sarac remains committed to his claim, having pursued Medtronic since 2008 over his patented stent design.
